2315 — Biocytogen Pharmaceuticals Beijing Co Share Price
- HK$3.32bn
- HK$3.45bn
- CNY716.91m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.9 | ||
Price to Tang. Book | 4.05 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 4.28 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -14.44% | ||
Return on Equity | -39.64% | ||
Operating Margin | -37.7% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | n/a | 253.54 | 354.56 | 533.88 | 716.91 | 918.78 | 1,144.55 | 41.41% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Biocytogen Pharmaceuticals Beijing Co Ltd is a China-based company mainly engaged in drug development business and preclinical research. The Company operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 13th, 2009
- Public Since
- September 1st, 2022
- No. of Employees
- 1,066
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 399,398,420
- Address
- No. 12, Beijing, 101111
- Web
- https://www.biocytogen.com.cn/
- Phone
- +86 1056967666
- Auditors
- KPMG
Upcoming Events for 2315
Biocytogen Pharmaceuticals Beijing Co Ltd Annual Shareholders Meeting
Similar to 2315
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:03 UTC, shares in Biocytogen Pharmaceuticals Beijing Co are trading at HK$8.30. This share price information is delayed by 15 minutes.
Shares in Biocytogen Pharmaceuticals Beijing Co last closed at HK$8.30 and the price had moved by -65.98% over the past 365 days. In terms of relative price strength the Biocytogen Pharmaceuticals Beijing Co share price has underperformed the FTSE Developed Asia Pacific Index by -65.95% over the past year.
The overall consensus recommendation for Biocytogen Pharmaceuticals Beijing Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Biocytogen Pharmaceuticals Beijing Co does not currently pay a dividend.
Biocytogen Pharmaceuticals Beijing Co does not currently pay a dividend.
Biocytogen Pharmaceuticals Beijing Co does not currently pay a dividend.
To buy shares in Biocytogen Pharmaceuticals Beijing Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$8.30, shares in Biocytogen Pharmaceuticals Beijing Co had a market capitalisation of HK$3.32bn.
Here are the trading details for Biocytogen Pharmaceuticals Beijing Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2315
Based on an overall assessment of its quality, value and momentum Biocytogen Pharmaceuticals Beijing Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biocytogen Pharmaceuticals Beijing Co is HK$17.69. That is 113.15% above the last closing price of HK$8.30.
Analysts covering Biocytogen Pharmaceuticals Beijing Co currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.24 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocytogen Pharmaceuticals Beijing Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -36.74%.
As of the last closing price of HK$8.30, shares in Biocytogen Pharmaceuticals Beijing Co were trading -33.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biocytogen Pharmaceuticals Beijing Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$8.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Biocytogen Pharmaceuticals Beijing Co's directors